Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | CA2 | P00918 | 5/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8024678 | 0.91 | CYP2C9 (0.83) | CYP2C9LMNACA2CA1CA9 | |
| SCHEMBL11929312 | 0.82 | LMNA (0.70) | CYP2C9LMNACA2CA1CA9 | |
| SCHEMBL11925202 | 0.80 | LMNA (0.67) | CYP2C9LMNACA2KDM4EALDH1A1 | |
| Methyclothiazide SCHEMBL5886113 | 0.75 | CHRM1 (0.71) | CYP2C9LMNACA2CA1CA9 | |
| SCHEMBL6297784 | 0.72 | CA2 (0.82) | CYP2C9LMNACA2CA1CA9 | |
| SCHEMBL8030116 | 0.72 | LMNA (0.56) | CYP2C9LMNACA2CA1CA9 | |
| SCHEMBL831407 | 0.72 | CYP2C9 (0.56) | CYP2C9LMNA | |
| SCHEMBL24871672 | 0.71 | LMNA (0.54) | CYP2C9LMNA | |
| SCHEMBL19754398 | 0.69 | LMNA (0.51) | CYP2C9LMNACA2CA1CA9 | |
| SCHEMBL8056407 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2676 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057876-A1 | METHODS FOR TREATING AND/OR PREVENTING LYMPHANGIOGENESIS-ASSOCIATED DISEASES BY USING GOLD NANOCLUSTERS | GOLDRED NANOBIOTECH CO., LTD. (TW) | 2025-02-20 | — | — | US | claimed |
| US-20240009249-A1 | ADIPOGENIC CELL COMPOSITIONS AND METHODS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2024-01-11 | — | — | US | claimed |
| WO-2023230770-A1 | METHODS OF LUNG ADENOCARCINOMA TREATMENT WITH NON ANTI-LUAD DRUGS OR COMPOUNDS | Suzhou Singleron Biotechnologies Co., Ltd. (CN) | 2023-12-07 | — | — | WO | claimed |
| US-20230381161-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | The George Institute for Global Health (AU) | 2023-11-30 | — | — | US | claimed |
| EP-4251175-A1 | ADIPOGENIC CELL COMPOSITIONS AND METHODS | Flagship Pioneering, Inc. (US) | 2023-10-04 | — | — | EP | claimed |
| WO-2023183932-A2 | MONOBODIES BINDING TO INTERCELLULAR ADHESION MOLECULE 2 (ICAM-2) | NEW YORK UNIVERSITY (US) | 2023-09-28 | — | — | WO | claimed |
| WO-2023111607-A1 | VALORISATION OF MARINE ANIMAL BY-PRODUCTS | Goia Limited (MU) | 2023-06-22 | — | — | WO | claimed |
| US-20230125076-A1 | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION | The George Institute for Global Health (AU) | 2023-04-27 | — | — | US | claimed |
| US-20220390453-A1 | OVARIAN CANCER BIOMARKER AND METHODS OF USING SAME | Women's College Hospital (CA) | 2022-12-08 | — | — | US | claimed |
| WO-2022115609-A1 | ADIPOGENIC CELL COMPOSITIONS AND METHODS | FLAGSHIP PIONEERING, INC. (US) | 2022-06-02 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1086129-A1 | ANTI-ANGIOGENIC PROTEINS AND METHODS OF USE THEREOF | Beth Israel Deaconess Medical Center (US) | 2001-03-28 | — | — | EP | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| WO-2000001410-A9 | METHODS OF INHIBITING PROLIFERATIVE DISEASES BY INHIBITING TGF-BETA MEDIATED ANGIOGENESIS | BETH ISRAEL HOSPITAL (US) | 2000-05-25 | — | — | WO | claimed |
| WO-2000001410-A1 | METHODS OF INHIBITING PROLIFERATIVE DISEASES BY INHIBITING TGF-BETA MEDIATED ANGIOGENESIS | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2000-01-13 | — | — | WO | claimed |
| WO-1999065940-A1 | ANTI-ANGIOGENIC PROTEINS AND METHODS OF USE THEREOF | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 1999-12-23 | — | — | WO | claimed |
| US-5811547-A | Method for inducing crystalline state transition in medicinal substance | NIPPON SHINYAJU CO., LTD. (JP) | 1998-09-22 | — | — | US | claimed |
| EP-0753301-A1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-15 | — | — | EP | claimed |
| EP-0628313-A1 | Combination of benzimidazoles having angiotensin-II antagonistic activity with dinretics or calcium antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-12-14 | — | — | EP | claimed |